VERACYTE, INC. (VCYT) 8-K Current Report: March 16, 2026
Filed: March 16, 2026
Health Care
Services-Medical LaboratoriesVERACYTE, INC. (VCYT) 8-K current report filed with SEC EDGAR on March 16, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 5.02: Departure/Election of Directors or Officers
VERACYTE, INC. 8-K Mar 16, 2026 Event Analysis
Item 5.02 · Departure/Election of Directors or Officers
- • New C-suite role: Dr. Kevin Haas (age 40) appointed Chief Development and Technology Officer, effective March 24, 2026
- • Recruited from Myriad Genetics (MYGN) where he served as CTO since 2021, bringing deep genomics/bioinformatics expertise directly relevant to VCYT's diagnostic platform
- • Base salary $500,000 with 55% target bonus, implying total cash target of ~$775,000
- • Equity package totals $3,000,000 target value — $1.5M in RSUs (4-year vest) and $1.5M in performance-based RSUs tied to Compensation Committee objectives
- • New dedicated CDT Officer role signals strategic prioritization of technology and R&D development as a growth lever
Other VERACYTE, INC. 8-K Filings
Get deeper insights on VERACYTE, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.